MARIEC.C-PHARMA: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
MARIEC.C-PHARMA
Largest movements
- Tangible fixed assets +€490,805
up €490,805 (+2,486%), from €19,741 to €510,546
- Cash -€185,218
down €185,218 (-66.7%), from €277,591 to €92,373
mainly Investment in fixed assets (net) (-€562,555) and Net result for the year (-€127,351)
- Stocks and contracts -€70,186
no longer reported in 2025 (was €70,186)
- Receivables within one year -€24,904
down €24,904 (-15.2%), from €163,564 to €138,660
of which Other amounts receivable: -€99,195
- Debts after one year +€450,000
new in 2025: €450,000
- Profit (loss) carried forward -€127,351
down €127,351 (-64.3%), from €198,156 to €70,805
- Trade debts -€93,684
down €93,684 (-89.6%), from €104,535 to €10,851
- Short-term financial debts -€19,500
no longer reported in 2025 (was €19,500)
- Depreciation +€51,257
up €51,257 (+201%), from €25,439 to €76,695
- Gross operating margin -€35,675
down €35,675, from €2,562 to -€33,113
- Financial charges +€7,014
up €7,014 (+6,786%), from €103 to €7,117
- Taxes +€3,824
up €3,824 (+57.9%), from €6,602 to €10,426
- Financial income -€1,381
no longer reported in 2025 (was €1,381)
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €553,972 | €759,407 | +€205,436 | +37.1% |
| Fixed assets | 21/28 | €42,515 | €528,374 | +€485,860 | +1,143% |
| Intangible fixed assets | 21 | €22,773 | €17,773 | -€5,000 | -22.0% |
| Tangible fixed assets | 22/27 | €19,741 | €510,546 | +€490,805 | +2,486% |
| Land and buildings | 22 | €19,741 | €510,546 | +€490,805 | +2,486% |
| Financial fixed assets | 28 | - | €55 | +€55 | |
| Current assets | 29/58 | €511,457 | €231,033 | -€280,424 | -54.8% |
| Stocks and contracts in progress | 3 | €70,186 | - | -€70,186 | |
| Stocks | 30/36 | €70,186 | - | -€70,186 | |
| Amounts receivable within one year | 40/41 | €163,564 | €138,660 | -€24,904 | -15.2% |
| Trade receivables | 40 | €33,369 | €107,660 | +€74,291 | +223% |
| Other amounts receivable | 41 | €130,195 | €31,000 | -€99,195 | -76.2% |
| Cash at bank and in hand | 54/58 | €277,591 | €92,373 | -€185,218 | -66.7% |
| Deferred charges and accrued income | 490/1 | €116 | - | -€116 | |
| Total equity and liabilities | 10/49 | €553,972 | €759,407 | +€205,436 | +37.1% |
| Equity | 10/15 | €415,761 | €288,410 | -€127,351 | -30.6% |
| Contributions | 10/11 | €18,550 | €18,550 | = | 0.0% |
| Reserves | 13 | €199,055 | €199,055 | = | 0.0% |
| Distributable reserves | 133 | €199,055 | €199,055 | = | 0.0% |
| Profit (loss) carried forward | 14 | €198,156 | €70,805 | -€127,351 | -64.3% |
| Amounts payable | 17/49 | €138,211 | €470,997 | +€332,786 | +241% |
| Amounts payable after more than one year | 17 | - | €450,000 | +€450,000 | |
| Financial debts | 170/4 | - | €450,000 | +€450,000 | |
| Amounts payable within one year | 42/48 | €138,211 | €20,997 | -€117,214 | -84.8% |
| Financial debts | 43 | €19,500 | - | -€19,500 | |
| Credit institutions | 430/8 | €19,500 | - | -€19,500 | |
| Trade debts | 44 | €104,535 | €10,851 | -€93,684 | -89.6% |
| Suppliers | 440/4 | €104,535 | €10,851 | -€93,684 | -89.6% |
| Taxes, remuneration and social security | 45 | €14,175 | €10,146 | -€4,029 | -28.4% |
| Taxes | 450/3 | €14,175 | €10,146 | -€4,029 | -28.4% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €25,439 | €76,695 | +€51,257 | +201% |
| Gross operating margin | 9900 | €2,562 | -€33,113 | -€35,675 | |
| Operating profit (loss) | 9901 | -€22,877 | -€109,808 | -€86,931 | -380% |
| Financial income | 75/76B | €1,381 | - | -€1,381 | |
| Recurring financial income | 75 | €1,381 | - | -€1,381 | |
| Financial charges | 65/66B | €103 | €7,117 | +€7,014 | +6,786% |
| Recurring financial charges | 65 | €103 | €7,117 | +€7,014 | +6,786% |
| Profit (loss) for the period before taxes | 9903 | -€21,599 | -€116,925 | -€95,326 | -441% |
| Income taxes | 67/77 | €6,602 | €10,426 | +€3,824 | +57.9% |
| Profit (loss) for the period | 9904 | -€28,201 | -€127,351 | -€99,150 | -352% |
| Profit (loss) for the period to be appropriated | 9905 | -€28,201 | -€127,351 | -€99,150 | -352% |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 30 October 2026 via checked.be.